GSA Capital Partners LLP Purchases New Holdings in Xencor, Inc. $XNCR

GSA Capital Partners LLP acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 34,520 shares of the biopharmaceutical company’s stock, valued at approximately $556,000.

A number of other hedge funds have also recently bought and sold shares of the company. Johnson & Johnson acquired a new position in shares of Xencor during the second quarter valued at $12,043,798,000. Jefferies Financial Group Inc. increased its position in Xencor by 620.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after purchasing an additional 620,440 shares during the period. Vanguard Group Inc. increased its position in Xencor by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after purchasing an additional 61,692 shares during the period. Dimensional Fund Advisors LP raised its holdings in Xencor by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after purchasing an additional 45,599 shares during the last quarter. Finally, Erste Asset Management GmbH raised its holdings in Xencor by 26.3% during the 4th quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock worth $7,347,000 after purchasing an additional 100,000 shares during the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on XNCR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Cantor Fitzgerald boosted their price target on shares of Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Wedbush increased their price objective on shares of Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Finally, Royal Bank Of Canada raised their price objective on shares of Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xencor currently has a consensus rating of “Hold” and a consensus price target of $24.86.

Xencor Trading Down 1.9%

NASDAQ:XNCR opened at $27.00 on Friday. Xencor, Inc. has a 1-year low of $7.13 and a 1-year high of $27.70. The business’s 50-day moving average price is $17.91 and its two-hundred day moving average price is $14.09. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -12.44 and a beta of 0.85.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.41) earnings per share. Sell-side analysts predict that Xencor, Inc. will post -3 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.